Navigation Links
CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.

The goal of Cellecta's second project with RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential cancer drug targets.

Mountain View, CA (PRWEB) September 16, 2009 -- Cellecta, Inc., a biotech contract research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic target and drug discovery, announced today that it has been awarded a subcontract to assist the scientists at Roswell Park Cancer Institute and Health Research, Inc. in developing a new technology for the discovery of cancer-related genes using HT insertional mutagenesis.

The Principal Investigator of this NIH-funded study, Dr. Eugene Kandel, states "There are many people who can appreciate new ideas about sophisticated molecular technologies when these are described on paper. There are some people who can implement such ideas in practice. And there are very few who can do it in a way that is robust, reproducible and easy for others to follow. That is why I am very happy to have the scientists of Cellecta helping me in the development of the new gene discovery method. These people were behind some of the most innovative techniques that had been popularized by renowned biotech companies, and now I am hoping for the same success for our method as well."

The Founder, CEO, and Scientific Director of Cellecta, Dr. Alex Chenchik, says that "Roswell Park Cancer Institute and Health Research, Inc. have both demonstrated a high level of confidence in Cellecta with this contract award, and we look forward to combining our efforts to develop a sophisticated and robust technology to accelerate the discovery of cancer-related genes."

About Cellecta, Inc.

Cellecta was founded in April of 2006 with a mission to develop the most advanced high-throughput (HT) RNAi and peptide screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs. The privately owned contract research service company is headed by an experienced management and product development team with a good product development track record, a network of outside scientific collaborators, and prior experience in start-up company operations. The team's six years of experience performing HT RNAi screens with pooled lentiviral shRNA libraries designed for HT sequencing, HT screening for bioactive peptides, HT functional validation of shRNA, stable cell line development, and HT insertional mutagenesis has resulted in some of the most advanced technologies available, developed in collaboration with opinion leaders and with funding from nine NIH SBIR grants. For more information, visit the Cellecta website, call 1-877-938-3910, or email us at info(at)cellecta(dot)com.

About Roswell Park Cancer Institute

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit the Roswell Park Cancer Institute website, call 1-877-ASK-RPCI (1-877-275-7724,) or email askrpci(at)roswellpark(dot)org.

About Health Research, Inc.

Health Research, Incorporated (HRI) is a not-for-profit corporation affiliated with the New York State Department of Health (DOH) and the Roswell Park Cancer Institute (RPCI), a leading cancer research center located in Buffalo, NY. HRI's mission is to assist DOH and RPCI to effectively evaluate, solicit, and administer external financial support for DOH and RPCI projects and to disseminate the benefits of DOH expertise through programs such as technology transfer.

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
7. Vical Names Andrew de Guttadauro Vice President, Corporate Development
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. SemBioSys updates Apo AI development program
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
Related Image:
CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... , Oct.12, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental ... which had been filed against the Company has been ... Petit , Chairman and CEO, stated, "As we suspected, ...
(Date:10/12/2015)... 2015 cell surface marker detection market ... according to a new report by Grand View Research, Inc. ... incidence of oncology diseases and other cell-associated disorders. --> ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ...
(Date:10/12/2015)... Oct. 12, 2015  Patara Pharma, a clinical-stage ... inflammatory diseases and conditions, today announced the closing ... financing. Concurrent with the close of its sale ... Loan and Security Agreement with Silicon Valley Bank ... million. Patara will use the funds from the ...
Breaking Biology Technology:
(Date:9/10/2015)... This report provides detailed descriptions of the ... emerging sensor types that will dominate in the future. ... the wearable technology hype curve in the last five ... feature with all of them is the prominence of ... useful functions. Sensors collect data about the physical and ...
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
(Date:9/10/2015)... Conn. , Sept. 10, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... based ecommerce site, Touch of Modern, will feature ... Wednesday, September 16 th . ... wide range of designer lifestyle products to its 7.2 ...
Breaking Biology News(10 mins):